Heron Therapeutics
HRTX
161 hedge funds and large institutions have $176M invested in Heron Therapeutics in 2024 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 42 increasing their positions, 51 reducing their positions, and 35 closing their positions.
7,109% more call options, than puts
Call options by funds: $4.61M | Put options by funds: $64K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
4.75% less ownership
Funds ownership: 80.32% → 75.57% (-4.8%)
7% less funds holding
Funds holding: 173 → 161 (-12)
18% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 51
26% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 35
27% less capital invested
Capital invested by funds: $242M → $176M (-$66.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.99M |
| 2 |
Morgan Stanley
New York
|
+$1.66M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.13M |
| 4 |
CPC
Congress Park Capital
Saratoga Springs,
New York
|
+$774K |
| 5 |
QOP
Quinn Opportunity Partners
Charlottesville,
Virginia
|
+$616K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.58M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$2.28M |
| 3 |
Goldman Sachs
New York
|
-$1.71M |
| 4 |
Renaissance Technologies
New York
|
-$1.33M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$1.28M |
HRTX Hedge Fund Activity: Q4 2024 in Review
161 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q4 2024, worth a combined $176M — down 27% from $242M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of HRTX and 26 opened new positions — a net loss of 9 holders — while 51 trimmed existing stakes and 42 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $4.99M. The largest seller was Citadel Advisors, exiting entirely with an estimated $2.58M sold.
- 161 institutional investors held Heron Therapeutics (HRTX) as of Q4 2024, down from 173 in Q3 2024.
- Funds reported $176M of Heron Therapeutics stock for Q4 2024, down 27% quarter-over-quarter.
- 26 funds opened new Heron Therapeutics positions in Q4 2024 and 35 closed out, a net change of -9 holders.
- The largest Heron Therapeutics buyer in Q4 2024 was Point72 Asset Management, an estimated $4.99M added.
- The largest Heron Therapeutics seller in Q4 2024 was Citadel Advisors, an estimated $2.58M sold.
Based on aggregated 13F filings for Q4 2024.